World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
84
Citations
45823
World Ranking
1333
National Ranking
685

William C. Gruber publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where William C. Gruber sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 259 publications — 54th percentile

54% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

William C. Gruber D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where William C. Gruber sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 84 D-Index — 73rd percentile

73% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

William C. Gruber is affiliated with Pfizer in the United States and has an extensive publication record in the field of medicine, with a focus on epidemiology and infectious diseases. Their research contributions span multiple topics, including respiratory infections, viral research, and public health.

Their recent papers include the following:

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, 2020, New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents, 2021, New England Journal of Medicine
  • Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants, 2023, New England Journal of Medicine

The scientist frequently collaborates with the following coauthors:

  • Kena A. Swanson (43 publications)
  • Alejandra Gurtman (38 publications)
  • David Cooper (37 publications)
  • Kathrin U. Jansen (35 publications)
  • Annaliesa S. Anderson (35 publications)

Their most common publication venues include:

  • Open Forum Infectious Diseases (18 publications)
  • New England Journal of Medicine (13 publications)
  • Vaccine (11 publications)
  • Clinical Infectious Diseases (7 publications)
  • The Journal of Infectious Diseases (6 publications)

Their main fields of study focus on medicine, with subfields in epidemiology, infectious diseases, microbiology, health, and public health, environmental and occupational health.

The primary topics of their work cover a range of subjects such as:

  • Pneumonia and Respiratory Infections
  • Respiratory viral infections research
  • SARS-CoV-2 and COVID-19 Research
  • Viral gastroenteritis research and epidemiology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Bacterial Infections and Vaccines
  • Influenza Virus Research Studies

Best Publications

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

    Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

    Marc J.M. Bonten;Susanne M. Huijts;Marieke Bolkenbaas;Chris Webber

  • The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children

    Robert B. Belshe;Paul M. Mendelman;John Treanor;James King

  • Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

    Unknown

  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

    Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

    Stephen J. Thomas;Edson D. Moreira;Nicholas Kitchin;Judith Absalon

  • Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.

    David W. Kimberlin;Chin Yu Lin;Richard F. Jacobs;Dwight A. Powell

  • Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

    Unknown

  • Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

    Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

  • Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era

    David W. Kimberlin;Chin-Yu Lin;Richard F. Jacobs;Dwight A. Powell

  • Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.

    Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Iksung Cho

  • Correlates of Immune Protection Induced by Live, Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine

    Robert B. Belshe;William C. Gruber;Paul M. Mendelman;Harshvardhan B. Mehta

  • Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.

    Richard J. Whitley;Gretchen Cloud;William Gruber;Gregory A. Storch

  • Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.

    Douglas M Fleming;Pietro Crovari;Ulrich Wahn;Timo Klemola

  • SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

    Ann R Falsey;Robert W Frenck;Edward E Walsh;Nicholas Kitchin

  • Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children.

    Bruce D. Forrest;Michael W. Pride;Andrew J. Dunning;Maria Rosario Z. Capeding

  • Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological Memory

    Andrés de Roux;B. Schmöele-Thoma;G. R. Siber;J. G. Hackell

  • Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections

    Shai Ashkenazi;Andre Vertruyen;Javier Arístegui;Susanna Esposito

  • Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants

    Ruth A. Karron;Peter F. Wright;Robert B. Belshe;Bhagvanji Thumar

  • Influenza virus infections in infants.

    W. Glezen;Larry Taber;Arthur Frank;William Gruber

Frequent Co-Authors

Daniel A. Scott
Daniel A. Scott Pfizer (United States)
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Robert W. Frenck
Robert W. Frenck Cincinnati Children's Hospital Medical Center
Peter F. Wright
Peter F. Wright Dartmouth College
Emilio A. Emini
Emilio A. Emini Pfizer (United States)
Robert B. Belshe
Robert B. Belshe Saint Louis University
Annaliesa S. Anderson
Annaliesa S. Anderson Pfizer (United States)
David A. Cooper
David A. Cooper University of New South Wales
Marc J. M. Bonten
Marc J. M. Bonten Utrecht University
Ron Dagan
Ron Dagan Ben-Gurion University of the Negev

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related online degrees in nursing can open diverse career paths in healthcare and research. Many professionals begin with foundational programs like the easiest ABSN program to get into, designed specifically for those transitioning from non-nursing backgrounds. These accelerated Bachelor of Science in Nursing programs offer a streamlined path to enter the nursing field quickly.

Once established in nursing, continuing education options such as the accelerated FNP programs provide a faster route to earn a Family Nurse Practitioner certification. This can enhance your clinical expertise while allowing you to address immunology-related health issues at a broader patient care level.

Transitioning further, nurses can pursue specialized credentials like the FNP to acute care certification, focusing on acute and emergency care settings. This pathway not only broadens practical skills but also aligns closely with immunological conditions requiring urgent intervention.

Additionally, for those without prior nursing experience, comprehensive online nursing programs for non nurses offer flexible entry points. These programs enable students to build foundational nursing knowledge that complements immunology studies and opens doors to numerous clinical and research roles.

Best Scientists Citing William C. Gruber

Trending Scientists

Recently Published Articles